UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Dermatology and therapy, 2023-12, Vol.13 (12), p.2929-2932

Menter, Alan

2023

Volltextzugriff (PDF)

Biologics for psoriasis: is there any unmet need left?

Expert opinion on biological therapy, 2022-12, Vol.22 (12), p.1429-1429

2022

Volltextzugriff (PDF)

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

Therapeutic Advances in Chronic Disease, 2018-01, Vol.9 (1), p.5-21

2018

Volltextzugriff (PDF)

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Journal of allergy and clinical immunology, 2015-07, Vol.136 (1), p.116-124.e7

2015

Volltextzugriff (PDF)

The use of cyclosporine in dermatology: Part I

Journal of the American Academy of Dermatology, 2010-12, Vol.63 (6), p.925-946

2010

Volltextzugriff (PDF)

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

The Lancet (British edition), 2015-08, Vol.386 (9993), p.541-551

2015

Volltextzugriff (PDF)

Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records

JAMA dermatology (Chicago, Ill.), 2022-10, Vol.158 (10), p.1142

2022

Volltextzugriff (PDF)

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Dermatology and Therapy, 2016-03, Vol.6 (1), p.1-12

2016

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1183-1190.e3

2014

Volltextzugriff (PDF)

Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas

Expert opinion on pharmacotherapy, 2018-04, Vol.19 (6), p.561-575

2018

Volltextzugriff (PDF)

Genital psoriasis is associated with significant impairment in quality of life and sexual functioning

Journal of the American Academy of Dermatology, 2015-06, Vol.72 (6), p.978-983

2015

Volltextzugriff (PDF)

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Journal of the American Academy of Dermatology, 2020-09, Vol.83 (3), p.839-846

2020

Volltextzugriff (PDF)

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Journal of the American Academy of Dermatology, 2015-10, Vol.73 (4), p.594-603

2015

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Journal of the American Academy of Dermatology, 2020-01, Vol.82 (1), p.161-201

2020

Volltextzugriff (PDF)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Drug design, development and therapy, 2018-01, Vol.12, p.3879-3883

2018

Volltextzugriff (PDF)

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

The New England journal of medicine, 2010-01, Vol.362 (2), p.118-128

2010

Volltextzugriff (PDF)

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

The Lancet (British edition), 2009-02, Vol.373 (9664), p.633-640

2009

Volltextzugriff (PDF)

Current and future management of psoriasis

The Lancet (British edition), 2007-07, Vol.370 (9583), p.272-284

2007

Volltextzugriff (PDF)

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Journal of investigative dermatology, 2020-09, Vol.140 (9), p.1784-1793.e2

2020

Volltextzugriff (PDF)

Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome

Human molecular genetics, 2011-10, Vol.20 (20), p.4025-4040

2011

Volltextzugriff (PDF)

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Journal of the American Academy of Dermatology, 2012-12, Vol.67 (6), p.1349-1361

2012

Volltextzugriff (PDF)

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2015-09, Vol.73 (3), p.410-419.e6

2015

Volltextzugriff (PDF)

A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin

Journal of investigative dermatology, 2012-03, Vol.132 (3), p.583-592

2012

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

1 – 25 von 605

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(458)
Mit Volltextzugriff
(464)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Dermatology
(323)
Science & Technology
(286)
Life Sciences & Biomedicine
(281)
Humans
(267)
Psoriasis
(139)
Psoriasis - Drug Therapy
(133)
Female
(130)
Male
(125)
Biological And Medical Sciences
(105)
Medical Sciences
(104)
Middle Aged
(101)
Adult
(96)
Treatment Outcome
(78)
Psoriasis. Parapsoriasis. Lichen
(73)
Severity Of Illness Index
(69)
Antibodies, Monoclonal - Therapeutic Use
(54)
Aged
(53)
Quality Of Life
(51)
Psoriasis - Pathology
(45)
Double-Blind Method
(44)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial

Biologics for psoriasis: is there any unmet need left?

Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

The use of cyclosporine in dermatology: Part I

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records

A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis

Guidelines of care for the management of psoriasis and psoriatic arthritis

Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment

Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas

Genital psoriasis is associated with significant impairment in quality of life and sexual functioning

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Current and future management of psoriasis

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome

Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Suchergebnisse filtern